Sensus Healthcare Q2 revenue misses estimates as unit sales fall

Sensus Healthcare

13/08/2026 21:31

Overview
U.S. medical device maker's Q2 revenue fell sharply and missed analyst expectations
Adjusted EBITDA loss widened yr/yr, reflecting lower unit sales and product mix
Revenue decline driven by lower unit sales, including delayed recognition of eight units due to financing approval timing

Outlook
Company expects to recognize revenue from eight units in Q3 due to delayed financing approval
CMS proposed 26% increase in hospital-based SRT delivery code, potentially improving reimbursement outlook
Company remains focused on delivering strong second-half 2026 performance

Result Drivers
DELAYED REVENUE RECOGNITION - Co said it could not record eight unit sales in Q2 due to financing approval timing; revenue is expected to be recognized in Q3
LOWER UNIT SALES - Fewer units were sold in Q2, including no sales to a historically large customer, contributing to the revenue decline
PRODUCT MIX AND INTERNATIONAL SHIPMENTS - Gross margin declined due to a higher proportion of international shipments with lower average selling prices and costs associated with Fair Deal Agreements

Company press release: ID:nBw6cYHNPa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$2.29 mln
$4.60 mln (4 Analysts)
Q2 Net Loss
 
$8.75 mln
 
Q2 Adjusted EBITDA
Miss
-$3.02 mln
-$2.71 mln (1 Analyst)
Q2 Loss Per Basic Share
 
$0.53
 
Q2 Operating Expenses
 
$3.95 mln
 
Q2 Pretax Loss
 
$3.06 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Sensus Healthcare Inc is $6.00, about 91.7% above its August 12 closing price of $3.13

Reuters Recommended Reads
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Aug 11 - Stereotaxis Q2 revenue misses estimates, dragged by system decline
Aug 12 - Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)